RESUMO
BACKGROUND: The prevalence of precocious puberty is increasing. Obesity has been demonstrated to be associated with changes in the adipokine profile and incidence of early puberty in girls. This study assessed the pubertal signs, the levels of adiponectin, resistin, and tumor necrosis factor-alpha (TNF-α) after 12 weeks of combined exercise and 4 weeks of detraining in overweight and obese girls with precocious puberty. METHODS: Thirty overweight and obese girls (aged 7-9) with precocious puberty, who had received Triptorelin, were randomly divided into two groups (15 exercise and 15 control). Initially, serum levels of adiponectin, resistin, TNF-α, luteinising hormone (LH), and follicle-stimulating hormone (FSH) and the signs of puberty progression (bone age, uterine length, and ovarian volume) were measured. The exercise group performed 60 min of combined (aerobic and resistance) exercise three times/week for 12 weeks. The control group did not receive any exercise. 48 h after the last training session and after 4 weeks of detraining, all research variables were measured (also in the control group). The statistical method used for data analysis was repeated measures ANOVA. RESULTS: In the exercise group, adiponectin significantly increased and resistin significantly decreased after 12 weeks. After 4 weeks of detraining, adiponectin significantly decreased, but resistin significantly increased. TNF-α levels did not change significantly during the study. There was no significant difference in all of the factors in the control group. Throughout the 16-week study period, the rate of puberty and LH significantly decreased in both exercise and control groups, but FSH, LH/FSH and ovarian volume significantly decreased in the exercise group alone (P<0.05). CONCLUSIONS: Combined exercise increased adiponectin and decreased resistin and the rate of puberty. However, after 4 weeks of detraining, these effects diminished but did not disappear. TRIAL REGISTRATION: IRCT, IRCT56471. Registered 25 may 2021 - Retrospectively registered, https://fa.irct.ir/user/profile.
Assuntos
Adipocinas/sangue , Exercício Físico , Sobrepeso/terapia , Puberdade Precoce/prevenção & controle , Pamoato de Triptorrelina/uso terapêutico , Adiponectina/sangue , Criança , Feminino , Hormônio Foliculoestimulante/sangue , Humanos , Hormônio Luteinizante/sangue , Sobrepeso/sangue , Sobrepeso/complicações , Obesidade Infantil/complicações , Obesidade Infantil/terapia , Puberdade Precoce/etiologia , Resistina/sangue , Resultado do Tratamento , Fator de Necrose Tumoral alfa/sangueRESUMO
Disorders of puberty can profoundly impact physical and psychosocial well-being. Precocious puberty is pubertal onset before eight years of age in girls and before nine years of age in boys. Patients with early isolated pubertal changes, prepubertal linear growth, and no worrisome neurologic symptoms typically have a benign pattern of development and should be monitored in the appropriate clinical context. Among patients with true precocious puberty, or full activation of the hypothalamic-pituitary-gonadal axis, most girls have an idiopathic etiology, whereas it is commonly due to identifiable pathology on imaging in boys. History and physical examination should be followed by measurements of serum follicle-stimulating hormone, luteinizing hormone, and testosterone (boys) or estradiol (girls); thyroid function testing; and bone age radiography. Brain magnetic resonance imaging should be performed in girls younger than six years, all boys with precocious puberty, and children with neurologic symptoms. Delayed puberty is the absence of breast development in girls by 13 years of age and absence of testicular growth to at least 4 mL in volume or 2.5 cm in length in boys by 14 years of age. Constitutional delay of growth and puberty is a common cause of delayed puberty; however, functional or persistent hypogonadism should be excluded. History and physical examination should be followed by measurements of serum follicle-stimulating hormone, luteinizing hormone, and testosterone (boys) or estradiol (girls); and bone age radiography. Abnormal growth velocity necessitates assessment of serum thyroid function, prolactin, and insulinlike growth factor I. Boys 14 years and older and girls 13 years and older may benefit from sex steroid treatment to jump-start puberty. Referral to a pediatric endocrinologist may be warranted after the initial evaluation.
Assuntos
Gonadotropinas Hipofisárias/sangue , Sistema Hipotálamo-Hipofisário , Puberdade Precoce/sangue , Puberdade Precoce/tratamento farmacológico , Maturidade Sexual , Adolescente , Idade de Início , Estatura , Criança , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Hormônios Esteroides Gonadais/sangue , Hormônio Liberador de Gonadotropina/sangue , Humanos , Hormônio Luteinizante/sangue , Masculino , Menarca , Puberdade Precoce/prevenção & controleRESUMO
OBJECTIVE: The present study was performed to investigate whether breast-feeding is associated with early pubertal development among children 7-9 years old in Korea. DESIGN: Children were divided into those who did and did not receive breast-feeding for 6 months or longer in accordance with the recommendations of the WHO. Pubertal status was determined by clinical examination using Tanner staging. SETTING: Prospective observational study. SUBJECTS: We conducted a follow-up study of children aged 7-9 years in 2011 who had taken part in the Ewha Birth & Growth Cohort study. RESULTS: Fifty (22.8%) of the total of 219 children were in early puberty, with the proportion being slightly higher for girls (24.1%) than boys (21.4%). Children who had entered early puberty were taller, weighed more and had a higher concentration of insulin-like growth factor 1. Moreover, the change in weight Z-score from birth to follow-up was significantly lower in children who were breast-fed than in those who were not (weight Z-score change: 0.32 (sd 1.59) v. 0.77 (sd 1.61), respectively, P=0.04). Comparison of breast-feeding by puberty status indicated a preventive association with early puberty in children who were breast-fed for 6 months or longer (OR=0.37; 95% CI 0.18, 0.74). This association remained significant after adjustment for relevant covariates. CONCLUSIONS: These results demonstrate a beneficial association between breast-feeding and early pubertal development, especially in those breast-fed for 6 months or longer. The study suggests that interventions would need to start early in life to prevent early pubertal development.
Assuntos
Aleitamento Materno , Desenvolvimento Infantil , Comportamento Materno , Política Nutricional , Cooperação do Paciente , Puberdade Precoce/prevenção & controle , Estatura/etnologia , Aleitamento Materno/etnologia , Criança , Estudos de Coortes , Feminino , Seguimentos , Humanos , Recém-Nascido , Fator de Crescimento Insulin-Like I/análise , Masculino , Comportamento Materno/etnologia , Cooperação do Paciente/etnologia , Estudos Prospectivos , Puberdade Precoce/sangue , Puberdade Precoce/epidemiologia , Puberdade Precoce/etnologia , República da Coreia/epidemiologia , Fatores de Risco , Aumento de Peso/etnologia , Organização Mundial da SaúdeRESUMO
AIMS: Precocious puberty (PP) may lead to many adverse outcomes. Recent evidence suggests that PP is a gut-brain disease. On the other hand, the use of glycyrrhizin, a natural sweetener, has become popular in the past decade. Glycyrrhizin possesses various health benefits, but its impact on PP has yet to be investigated. We aimed to explore the protective effects of glycyrrhizin against PP in both humans (observational) and animals (interventional). MATERIALS AND METHODS: In the human cohort, we investigated the association between glycyrrhizin consumption and risk of PP. In the animal experiment, we observed puberty onset after feeding danazol-induced PP rats with glycyrrizin. Blood, fecal, and hypothalamic samples were harvested to evaluate potential mechanistic pathways. We also performed a fecal microbiota transplantation to confirm to causal relationship between glycyrrhizin and PP risk. KEY FINDINGS: Glycyrrhizin exhibited a protective effect against PP in children (OR 0.60, 95%CI: 0.39-0.89, p = 0.013), primarily driven by its significance in girls, while no significant effect was observed in boys. This effect was consistent with findings in rodents. These benefits were achieved through the modulation of the gut microbiome, which functionally suppressed the hypothalamic-pituitary-gonadal axis and prevented PP progression. A fecal microbiota transplantation indicated that the causal correlation between glycyrrhizin intake and PP is mediated by the gut microbiome alterations. SIGNIFICANCE: Our findings suggest that glycyrrhizin can protect against PP by altering the gut microbiome. Long term use of glycyrrhizin is safe and tolerable. Therefore, glycyrrhizin can serve as a safe and affordable complementary therapy for PP.
Assuntos
Microbioma Gastrointestinal , Ácido Glicirrízico , Puberdade Precoce , Edulcorantes , Microbioma Gastrointestinal/efeitos dos fármacos , Ácido Glicirrízico/farmacologia , Animais , Ratos , Masculino , Feminino , Puberdade Precoce/prevenção & controle , Puberdade Precoce/tratamento farmacológico , Edulcorantes/farmacologia , Edulcorantes/efeitos adversos , Humanos , Criança , Ratos Sprague-Dawley , Transplante de Microbiota FecalRESUMO
This study aimed to explore the potential regulatory pathways of (-)-epigallocatechin-3-gallate (EGCG) in preventing obesity-related precocious puberty. A retrospective analysis on the impact of EGCG on puberty onset in obese girls was conducted on plasma samples collected from a human randomized controlled trial. In the trial, participants consumed EGCG capsules for 12 weeks. In the animal experiment, rats were divided into four groups: normal diet control (NC) group, high-fat diet (HFD) group, NC+EGCG group, and HFD+EGCG group. Blood samples were collected on postnatal days 27, 33, and 36 to detect sexual development indicators. The hypothalamic expressions of kisspeptin/Kiss1R and neurokinin B (NKB)/NK3R signaling were measured by RT-qPCR and Western blot assay. The ovary NKB protein expression was assessed by immunohistochemical assays. Serum NKB level in the EGCG group was lower than the placebo group by 0.599 ng/mL [ß=-0.599, 95% CI: (-1.005, -0.193)], at the end of intervention and after adjusting for confounders (clinical study). In the animal experiment, EGCG intervention could significantly delay the vaginal opening (VO) time of rats fed with HFD. On day 33, EGCG intervention could significantly reduce serum NKB, luteinizing hormone (LH) levels, ovarian NKB protein expression, and endometrial thickness of HFD-fed rats, while EGCG intervention could remarkably increase mRNA and protein expression of NKB/NK3R. EGCG could prevent obesity-related precocious puberty through NKB/NK3R signaling pathway, which may provide a novel insight into the role of EGCG in preventing precocious puberty in obese girls.
Assuntos
Camellia sinensis , Catequina , Obesidade , Puberdade Precoce , Animais , Camellia sinensis/química , Catequina/administração & dosagem , Catequina/análogos & derivados , Catequina/farmacologia , Feminino , Humanos , Neurocinina B/genética , Neurocinina B/metabolismo , Obesidade/complicações , Puberdade Precoce/etiologia , Puberdade Precoce/prevenção & controle , Ratos , Estudos Retrospectivos , Transdução de SinaisRESUMO
Introduction: While soy is suggested as a possible risk factor, exclusive breastfeeding (EBF) has a likely protective effect in precocious puberty. Our aim was to evaluate the association between both of these variables with central precocious puberty (CPP). Methods: We performed a retrospective, case-control study. A total of 161 girls were divided into two groups: 84 patients diagnosed with CPP composed the case group and 77 patients without the diagnosis of CPP (had gone through normal onset of puberty) were the control group. Results: Our control group had a higher presence of EBF >6 months, which was an important protective factor for CPP (OR: 0.5; IC 95%: 0.3-0.9, p = 0.05) and also correlated negatively with the presence of it (r = -0.2; p < 0.05). Oppositely, the use of soy was significantly higher in the CPP group, (OR: 3.8; IC 95%: 1.5-6, p < 0.05) and positively correlating (r = 0.2; p < 0.01) with the presence of CPP. Duration of soy intake (years) correlated with bone age (r = 0.415; p < 0.05). A logistic regression was performed to evaluate the effects of EBF duration and soy on CPP. The model was significant (x² (2) = 20,715, p = <0.001) and explained 12.2% (Nagelkerke R2) of the variance, correctly classifying 62.5% of cases. EBF was associated with a reduction of likelihood of having CPP [OR = 0,187 (CI = 0.055-0,635); Wald = 7,222, p = 0.007], while soy intake increased the risk [OR = 3.505 (CI) = 1,688-7,279, Wald = 11,319, p = 0.001]. Conclusion: Our data found the use of soy was associated with CPP. Additionally, EBF was pointed as a protective factor. However, future prospective studies are needed to clarify this issue.
Assuntos
Aleitamento Materno/métodos , Glycine max/efeitos adversos , Fatores de Proteção , Puberdade Precoce/prevenção & controle , Estudos de Casos e Controles , Criança , Feminino , Seguimentos , Humanos , Prognóstico , Puberdade Precoce/induzido quimicamente , Puberdade Precoce/patologia , Estudos RetrospectivosRESUMO
PURPOSE OF REVIEW: Aromatase inhibitors have been reported to increase height prediction in boys with short stature, and in boys and girls with gonadotropin-independent precocious puberty. The following review discusses data published since 2008 regarding the safety and efficacy of aromatase inhibitors in pediatric patients. RECENT FINDINGS: Third-generation aromatase inhibitors in combination with antiandrogens appear effective in preventing bone age advancement and virilization in boys with familial male-limited precocious puberty (FMPP). Letrozole, but not anastrozole, decreased bleeding episodes and bone age advancement in girls with McCune-Albright syndrome (MAS), despite ovarian enlargement. Letrozole-treated boys with idiopathic short stature (ISS) had no loss of bone density but were noted to have more vertebral abnormalities than a placebo group. Two years of letrozole therapy did not increase predicted adult height in pre and peripubertal boys with ISS when re-assessed 4 years after the treatment period. SUMMARY: Aromatase inhibitors together with an antiandrogen appear to be a very promising treatment for FMPP. Further longer-term studies with letrozole are needed in MAS. The prevalence of vertebral deformities should be evaluated prospectively in patients treated with aromatase inhibitors. Adult height data are still lacking in pediatric patients treated with aromatase inhibitors. Two years of therapy in pre and peripubertal short boys does not appear to increase adult height. Hemogram, lipids, and bone density should be periodically assessed in treated patients. Further controlled studies are needed to demonstrate safety and efficacy of aromatase inhibitors in pediatric patients.
Assuntos
Desenvolvimento do Adolescente/efeitos dos fármacos , Inibidores da Aromatase/uso terapêutico , Aromatase/sangue , Desenvolvimento Infantil/efeitos dos fármacos , Transtornos do Crescimento/tratamento farmacológico , Adolescente , Criança , Feminino , Transtornos do Crescimento/enzimologia , Humanos , Masculino , Prognóstico , Puberdade Precoce/enzimologia , Puberdade Precoce/prevenção & controleRESUMO
INTRODUCTION: Treatment with aromatase inhibitors (AI) is a potential novel treatment in patients with congenital adrenal hyperplasia (CAH) and advanced bone age (BA), to increase near adult height (NAH). Not much is known about the efficacy of AI treatment in CAH and how AI treatment will influence the management of corticosteroid treatment. CASE PRESENTATION: At the age of 6 years and 3 months, a boy with salt-losing CAH presented with a BA 7 years in advance. Treatment with an AI (exemestane) was initiated to decelerate bone maturation. We continued the standard dosage of corticosteroid treatment. Precocious puberty was treated with 4 years of gonadotropin-releasing hormone agonist, while AI treatment was continued until attainment of NAH. His NAH 177.7 cm (-0.8 SDS) was considerably higher than his predicted adult height of 151.3 cm (-4.6 SDS) at the start of AI treatment. The higher serum androgen levels during AI treatment did not result in short adult stature. DISCUSSION/CONCLUSION: This report shows that AI treatment can adequately decelerate bone maturation, causing predicted adult height to increase significantly in patients of CAH with accelerated bone maturation. We suggest continuing the same corticosteroid dosage during AI treatment and accepting higher serum androgen levels.
Assuntos
Hiperplasia Suprarrenal Congênita/tratamento farmacológico , Hiperplasia Suprarrenal Congênita/fisiopatologia , Determinação da Idade pelo Esqueleto , Androstadienos/uso terapêutico , Inibidores da Aromatase/uso terapêutico , 17-alfa-Hidroxiprogesterona/sangue , Androstenodiona/sangue , Estatura , Desenvolvimento Ósseo/efeitos dos fármacos , Desenvolvimento Ósseo/fisiologia , Criança , Seguimentos , Hormônio Liberador de Gonadotropina/agonistas , Hormônio Liberador de Gonadotropina/uso terapêutico , Humanos , Hidrocortisona/administração & dosagem , Masculino , Puberdade/efeitos dos fármacos , Puberdade/fisiologia , Puberdade Precoce/prevenção & controleRESUMO
Congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency is a rare autosomal recessive genetic disorder. It is caused by reduced or absent activity of 11ß-hydroxylase (CYP11B1) enzyme and the resultant defects in adrenal steroidogenesis. The most common clinical features of 11 beta-hydroxylase deficiency are ambiguous genitalia, accelerated skeletal maturation and resultant short stature, peripheral precocious puberty and hyporeninemic hypokalemic hypertension. The biochemical diagnosis is based on raised serum 11-deoxycortisol and 11-deoxycorticosterone levels together with increased adrenal androgens. More than 100 mutations in CYP11B1 gene have been reported to date. The level of in-vivo activity of CYP11B1 relates to the degree of severity of 11 beta-hydroxylase deficiency. Clinical management of 11 beta-hydroxylase deficiency can pose a challenge to maintain adequate glucocorticoid dosing to suppress adrenal androgen excess while avoiding glucocorticoid-induced side effects. The long-term outcomes of clinical and surgical management are not well studied. This review article aims to collate the current available data about 11 beta-hydroxylase deficiency and its management.
Assuntos
Hiperplasia Suprarrenal Congênita/tratamento farmacológico , Hiperplasia Suprarrenal Congênita/diagnóstico , Hiperplasia Suprarrenal Congênita/genética , Hiperplasia Suprarrenal Congênita/fisiopatologia , Animais , Diagnóstico Precoce , Glucocorticoides/efeitos adversos , Glucocorticoides/uso terapêutico , Terapia de Reposição Hormonal/efeitos adversos , Humanos , Hidrocortisona/efeitos adversos , Hidrocortisona/uso terapêutico , Hipertensão/etiologia , Hipertensão/prevenção & controle , Mutação , Guias de Prática Clínica como Assunto , Puberdade Precoce/etiologia , Puberdade Precoce/prevenção & controle , Índice de Gravidade de Doença , Esteroide 11-beta-Hidroxilase/genética , Esteroide 11-beta-Hidroxilase/metabolismoRESUMO
CONTEXT AND OBJECTIVE: Girls with precocious pubarche (PP, pubic hair at < 8 yr of age) are at high risk for early onset and rapid progression of puberty, in particular if their prenatal growth was restrained, i.e. low birth weight (LBW), and followed by rapid postnatal catch-up of weight gain. We postulated that insulin resistance contributes to early onset and rapid progression of puberty in LBW-PP girls and thus explored the puberty-delaying effects of insulin sensitization with metformin initiated shortly after PP diagnosis. SETTING, DESIGN, AND PATIENTS: The study population consisted of 38 prepubertal LBW girls with PP attributed to exaggerated adrenarche [mean body weight, 2.4 kg; age, 7.9 yr; body mass index (BMI), 18.4 kg/m(2)]. These girls were randomly assigned to remain untreated (n = 19) or to receive metformin (n = 19; 425 mg/d) for 2 yr. MAIN OUTCOME MEASURES: Pubertal staging, age at menarche, body composition by absorptiometry, fasting insulin, glucose, lipids, leptin, IGF-I, IGF-binding protein-1, testosterone, dehydroepiandrosterone sulfate, and SHBG were the main outcome measures. RESULTS: Metformin treatment was associated with a less adipose body composition (and lower serum leptin levels) and with a 0.4-yr delay in the clinical onset of puberty (Tanner B2; 9.5 vs. 9.1 yr; P < 0.01). These findings were corroborated by a delay of at least 1 yr in the puberty-associated rise of circulating IGF-I (P < 0.01). Available results also point to a metformin-associated delay of menarche (P < 0.02). Gain in height and lean mass was not divergent between study subgroups. CONCLUSION: The efficacy of early metformin treatment in PP girls is here extended to include not only a less adipose body composition after 2 yr but also a less advanced onset of puberty, whereas height gain is maintained. These findings open the perspective that, ultimately, metformin treatment may also prove to heighten the short adult stature of LBW-PP girls.
Assuntos
Hipoglicemiantes/uso terapêutico , Metformina/uso terapêutico , Puberdade Precoce/prevenção & controle , Adrenarca , Composição Corporal , Índice de Massa Corporal , Criança , Feminino , Humanos , Recém-Nascido de Baixo Peso , Recém-Nascido , Fator de Crescimento Insulin-Like I/análise , PuberdadeRESUMO
A 4-10/12 year-old boy presented with tall stature and advanced secondary sexual characteristics. His bone age was 13 years giving him a height prediction of 147 cm. An initial 11-deoxycortisol level of 13,770 ng/dl and associated hypertension suggested the diagnosis of 11-hydroxylase deficiency, which was confirmed by dexamethasone suppression and genotyping. Treatment strategy was based on the premise that known hypothalamic priming resulting in early pubertal development could be averted by delaying puberty with leuprolide; also that effects of hydrocortisone and leuprolide on attenuating growth could be counteracted by growth hormone. The combined treatment resulted in a final height at age 12 years which was 25.4 cm greater than predicted, and bone density above average. We conclude that delaying puberty until an appropriate age, offsetting growth suppression, and improving bone mineralization can be effectively achieved using glucocorticoids, leuprolide and growth hormone in patients with 11-hydroxylase deficiency.
Assuntos
Hiperplasia Suprarrenal Congênita/tratamento farmacológico , Hormônio do Crescimento Humano/uso terapêutico , Hidrocortisona/uso terapêutico , Leuprolida/administração & dosagem , Hiperplasia Suprarrenal Congênita/enzimologia , Hiperplasia Suprarrenal Congênita/genética , Estatura/efeitos dos fármacos , Estatura/fisiologia , Densidade Óssea/efeitos dos fármacos , Densidade Óssea/fisiologia , Criança , Preparações de Ação Retardada , Genótipo , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/fisiopatologia , Estudos Longitudinais , Masculino , Puberdade Precoce/prevenção & controle , Esteroide 11-beta-Hidroxilase/genética , Esteroide 11-beta-Hidroxilase/metabolismoRESUMO
Precocious puberty which impacts children physically and psychologically has become one of the health problem over the world. However, the mechanism and preventive measures of precocious puberty is still not clear. Recent studies suggested that leptin may act as the 'permissive factor' to initiate the puberty by regulating gonadotrophin-releasing hormone secretion. Previous evidence from animal and human studies found that tea polyphenols can reduce serum leptin levels in vivo and inhibit the expression of leptin in adipose tissue. This article focus on whether tea polyphenols could delay the onset of puberty by reducing leptin levels. To verify the possibility of tea polyphenols on preventing precocious puberty, animal experiment can be used. Our hypothesis that tea polyphenols could prevent the precocious puberty may provide important potential way for the prevention and control of children precocious puberty.
Assuntos
Polifenóis/química , Puberdade Precoce/prevenção & controle , Chá/química , Animais , Feminino , Hormônio Liberador de Gonadotropina/metabolismo , Humanos , Leptina/sangue , Leptina/química , Hormônio Luteinizante/metabolismo , Masculino , Camundongos , Ratos , Ratos Sprague-Dawley , Maturidade Sexual , Vagina/efeitos dos fármacosRESUMO
BACKGROUND: The objective of this study was to identify variables that might interfere with reaching the near final height (NFH) in Congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency (21-OHD). METHODS: A cross-sectional study of 82 (24 males and 58 females) classic (23 salt-wasting form [SW] and 59 simple-virilizing form [SV]) CAH 21-OHD patients seen in our institution between 1989 and 2015 with 10.6 (0.5~25.5) years of follow-up who reached their NFH was conducted. The variables related to NFH were explored. RESULTS: NFH (153.35±8.31) cm, (-1.9±1.1) SD was significantly lower than the normal population (p<0.001). The treated patients reached a significantly higher NFH (-1.7±1.1) SD than those untreated (-2.6±1.0) SD (p<0.05). Both of early treatment and late treatment group were taller than untreated group (p<0.001, p=0.013, respectively), and early treatment group had a taller height trend than late treatment group (p=0.089). A better height outcome was observed in patients with advantage in target height, good compliance, and low hydrocortisone dose by multivariate Cox regression analysis in 62 treatment patients. NFH and hydrocortisone dose was negatively correlated (r=-0.23, p=0.078) in treated group. Patients complicated by central precocious puberty (CPP) received gonadotropin-releasing hormone analogue (GnRHa) plus letrozole had increased NFH with height SD for bone age and Ht SD improved after treatment compare to no intervention group (p=0.001, p=0.035). CONCLUSIONS: Patients with classic 21-OHD have blunted final height, as compared with their target height and the population norm, not-treated even worse. Careful treatment adjustments have a favorable influence on growth. Alternative treatments, such as the use of puberty inhibitors GnRHa in addition to anti-estrogen therapy letrozole can somewhat improve NFH in children with 21-OHD complicated by CPP.
Assuntos
Hiperplasia Suprarrenal Congênita/terapia , Transtornos do Crescimento/prevenção & controle , Adolescente , Hiperplasia Suprarrenal Congênita/etnologia , Hiperplasia Suprarrenal Congênita/fisiopatologia , Estatura/etnologia , Criança , Pré-Escolar , China , Estudos de Coortes , Terapia Combinada , Estudos Transversais , Feminino , Seguimentos , Transtornos do Crescimento/etnologia , Transtornos do Crescimento/etiologia , Transtornos do Crescimento/fisiopatologia , Hospitais Universitários , Humanos , Lactente , Recém-Nascido , Masculino , Ambulatório Hospitalar , Modelos de Riscos Proporcionais , Puberdade Precoce/etnologia , Puberdade Precoce/etiologia , Puberdade Precoce/fisiopatologia , Puberdade Precoce/prevenção & controle , Estudos Retrospectivos , Índice de Gravidade de DoençaRESUMO
Gonadotropin independent sexual precocity (SP) may be due to congenital adrenal hyperplasia (CAH), and its timing usually depends on the type of mutation in the CYP21A2 gene. Compound heterozygotes are common and express phenotypes of varying severity. The objective of this case report was to investigate the hormonal pattern and unusual genetic profile in a 7-year-old boy who presented with pubic hair, acne, an enlarged phallus, slightly increased testicular volume and advanced bone age. Clinical, hormonal and genetic studies were undertaken in the patient as well as his parents. We found elevated serum 17-hydroxyprogesterone (17-OHP) and androstenedione that were suppressed with dexamethasone, and elevated testosterone that actually rose after giving dexamethasone, indicating activity of the hypothalamic-pituitary-gonadal (HPG) axis. An initial search for common mutations was negative, but a more detailed genetic analysis of the CYP21A2 gene revealed two mutations including R341W, a non-classical mutation inherited from his mother, and g.823G>A, a novel not previously reported consensus donor splice site mutation inherited from his father, which is predicted to be salt wasting. However, the child had a normal plasma renin activity. He was effectively treated with low-dose dexamethasone and a GnRH agonist. His father was an unaffected carrier, but his mother had evidence of mild non-classical CAH. In a male child presenting with gonadotropin independent SP it is important to investigate adrenal function with respect to the androgen profile, and to carry out appropriate genetic studies.
Assuntos
Hiperplasia Suprarrenal Congênita/genética , Mutação , Esteroide 21-Hidroxilase/genética , Hiperplasia Suprarrenal Congênita/sangue , Hiperplasia Suprarrenal Congênita/tratamento farmacológico , Hiperplasia Suprarrenal Congênita/fisiopatologia , Substituição de Aminoácidos , Criança , Hormônio Liberador de Gonadotropina/antagonistas & inibidores , Heterozigoto , Humanos , Íntrons , Leuprolida/uso terapêutico , Masculino , Puberdade Precoce/etiologia , Puberdade Precoce/prevenção & controle , Testosterona/antagonistas & inibidores , Testosterona/sangue , Resultado do TratamentoAssuntos
Beneficência , Cuidadores , Defesa da Criança e do Adolescente , Crianças com Deficiência , Comissão de Ética , Deficiência Intelectual/enfermagem , Esterilização Involuntária/ética , Adulto , Criança , Conflito de Interesses , Tomada de Decisões/ética , Deficiências do Desenvolvimento/enfermagem , Comissão de Ética/legislação & jurisprudência , Consultoria Ética , Feminino , Assistência Domiciliar , Humanos , Histerectomia/ética , Deficiência Intelectual/complicações , Deficiência Intelectual/etiologia , Mastectomia/ética , Pais , Puberdade Precoce/prevenção & controle , Argumento RefutávelAssuntos
Cuidadores , Conflito de Interesses , Comissão de Ética , Consultoria Ética , Assistência Domiciliar , Deficiência Intelectual/enfermagem , Política Pública/legislação & jurisprudência , Esterilização Involuntária/ética , Adulto , Asfixia Neonatal/complicações , Tamanho Corporal/efeitos dos fármacos , Criança , Defesa da Criança e do Adolescente , Tomada de Decisões/ética , Deficiências do Desenvolvimento/enfermagem , Crianças com Deficiência , Estrogênios/administração & dosagem , Comissão de Ética/legislação & jurisprudência , Feminino , Humanos , Histerectomia/ética , Recém-Nascido , Deficiência Intelectual/complicações , Deficiência Intelectual/etiologia , Mastectomia/ética , New Jersey , Pais , Puberdade Precoce/prevenção & controle , Esterilização Involuntária/legislação & jurisprudênciaAssuntos
Cuidadores , Conflito de Interesses , Tomada de Decisões/ética , Deficiência Intelectual/enfermagem , Obrigações Morais , Esterilização Involuntária/ética , Adulto , Tamanho Corporal/efeitos dos fármacos , Criança , Defesa da Criança e do Adolescente , Deficiências do Desenvolvimento/enfermagem , Crianças com Deficiência , Estrogênios/administração & dosagem , Comissão de Ética , Consultoria Ética , Feminino , Assistência Domiciliar , Humanos , Histerectomia/ética , Deficiência Intelectual/complicações , Deficiência Intelectual/etiologia , Mastectomia/ética , Pais , Puberdade Precoce/prevenção & controle , Incerteza , Argumento RefutávelAssuntos
Cuidadores , Conflito de Interesses , Tomada de Decisões/ética , Crianças com Deficiência , Comissão de Ética , Deficiência Intelectual/enfermagem , Pais , Esterilização Involuntária/ética , Decisões da Suprema Corte , Adulto , Tamanho Corporal/efeitos dos fármacos , Criança , Defesa da Criança e do Adolescente , Comportamento de Escolha/ética , Deficiências do Desenvolvimento/enfermagem , Estrogênios/administração & dosagem , Comissão de Ética/legislação & jurisprudência , Consultoria Ética , Feminino , Assistência Domiciliar , Humanos , Histerectomia/ética , Deficiência Intelectual/complicações , Deficiência Intelectual/etiologia , Mastectomia/ética , Países Baixos , Puberdade Precoce/prevenção & controle , Esterilização Involuntária/legislação & jurisprudência , Estados UnidosRESUMO
BACKGROUND: McCune-Albright syndrome (MAS) is a genetic disorder characterized by the triad of fibrous dysplasia, skin hyperpigmentation, and autonomous hyperfunction of various endocrine organs. MAS frequently presents in females as precocious puberty (PP). Although many treatments have been proposed, the preservation of final height (FH) in these patients remains a challenge. OBJECTIVES: To evaluate the efficacy of tamoxifen in improving the FH prediction (FHP) in patients with MAS. METHOD: We retrospectively analyzed 8 female patients with MAS who presented with café-au-lait spots and gonadotropin-independent PP. The patients were followed for a mean period of 8.3 years (range: 3-16). RESULTS: All patients were treated with tamoxifen (10-20 mg/day) for 3-8 years (mean ± SD: 5.75 ± 2.05), which resulted in the cessation of vaginal bleeding and the stabilization of bone age maturation. There was a significant difference between the FHP at the beginning of treatment and at the end of treatment (145.1 ± 8.6 cm; Z score -2.84 ± 1.44 cm) and at the last evaluation (157.0 ± 9.2 cm; Z score -0.85 ± 0.54 cm; p < 0.001). CONCLUSION: Our results support a role for tamoxifen in improving the FHP in patients with MAS.